Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrated medical technology company focused on developing and commercializing novel technologies for weight loss. Obalon has launched the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
|Second Quarter 2017 Press Release|
|Second Quarter 2017 10Q|
OBLN (Common Stock) $8.56 - 0.28 (3.17%)
Data provided by Nasdaq. Minimum 15 minutes delayed.
Obalon Announces Second Quarter 2017 Financial Results
Obalon Announces Upcoming Conference Presentation
Obalon Schedules Second Quarter 2017 Financial Results Conference Call for August 2, 2017 at 8:30 a.m. Eastern Time
Obalon Therapeutics, Inc. to Present at UBS Global Healthcare Conference
|There are currently no events scheduled.|